The main purpose of this study is to learn about the safety and tolerability of LY3437943 when given to Chinese participants with overweight body mass index (BMI) or obesity. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last about 20 weeks excluding screening period and may include up to 20 visits to the study center.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
32
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Peking University First Hospital
Beijing, China
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through Week 20
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943
PK: Cmax of LY3437943
Time frame: Predose through Day 109
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3437943
PK: AUC of LY3437943
Time frame: Predose through Day 109
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.